Company intelligence / Profile preview

VitreoRetinal Technologies, Inc.

Irvine, California, United Statesvitreoretinaltech.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

VitreoRetinal Technologies, Inc. developed ophthalmic drugs targeting retinal diseases. Its lead candidate, Vitreosolve®, was evaluated in multinational Phase III trials for inducing posterior vitreous detachment in patients with nonproliferative diabetic retinopathy. The company also explored treatments for glaucoma and retinitis pigmentosa but appears to have ceased operations after its main clinical programs stalled or were terminated. No recent clinical results are available beyond early trial phases.

Therapeutic areas: Ophthalmology
Modalities: Small molecules (notably enzymatic agents for vitreolysis)
Industry: Biotech

Drug pipeline

1 asset

Vitreosolve

Partnerships

De Novo Ventures led Series A financing round ($8.8M); no major pharma partnerships disclosed.

Beyond the preview

Go deeper on VitreoRetinal Technologies, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VitreoRetinal Technologies, Inc..